![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2007, American Society for Microbiology Departments of Pathobiology,1 Oral Biology,2 Medicine, University of Washington, Seattle, Washington 981953 *Corresponding author. Mailing address: Department of Medicine, Box 359779, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104. Phone: (206) 341-5362. Fax: (206) 341-5363. E-mail: lukehart/at/u.washington.edu Received October 26, 2006; Revised December 5, 2006; Accepted February 14, 2007. This article has been cited by other articles in PMC.Abstract Treponema denticola, a periodontal pathogen, is relatively resistant to human beta-defensins, which are small cationic antimicrobial peptides produced by a number of cells, including the gingival epithelium. Using two independent methods, we previously demonstrated that T. denticola proteases are not responsible for decreased vulnerability to defensins. In this study, we confirmed that the major outer membrane protease, dentilisin, is not responsible for T. denticola insensitivity to defensins and examined several other possible mechanisms, including reduced binding to the bacterial surface and efflux pump activity. It has been suggested that some bacteria mask their surfaces with serum proteins. T. denticola grown in a serum-free medium did not exhibit increased susceptibility to human beta-defensin 2 and 3 (hβD-2 and hβD-3, respectively), suggesting that cloaking of the outer surface with host proteins is not involved in defensin resistance. Nonetheless, we demonstrated that T. denticola binds significantly less hβD-2 and -3 than susceptible organisms bind, suggesting that the unusual outer membrane composition of T. denticola may discourage cationic peptide binding. Efflux pumps have been shown to mediate resistance to antibiotics and cationic peptides in other bacteria, and their role in T. denticola's relative resistance to β-defensins was investigated. Three inhibitors of bacterial ATP-binding cassette (ABC) efflux pumps had no effect on T. denticola's susceptibility to hβD-2 or -3. In contrast, a proton motive force inhibitor, carbonyl cyanide 3-chlorophenylhydrazone, increased the susceptibility of T. denticola to killing by hβD-3, demonstrating a potential role for efflux pumps (other than ABC pumps) in resistance to this peptide. Our data suggest that the combination of decreased defensin binding and efflux of any peptide which enters the cytoplasm may explain T. denticola's relative resistance to human beta-defensins. Periodontal disease is remarkably widespread, afflicting 50% of adults in the United States (38, 62), and severe disease affects 6 million Americans. There is interest in using synthetic antimicrobial peptides as an adjunct to traditional therapies for periodontal disease (26, 45, 73). Humans naturally produce several antimicrobial peptides, including the epithelium-derived β-defensins, which have microbicidal activity against Porphyromonas gingivalis, actinomycetes, streptococci, and Candida species in vitro (34, 39, 47). However, we have previously determined that Treponema denticola, a major component of the “red complex” microflora associated with periodontitis (70), is not sensitive to β-defensins (9, 70). Other suspected periodontal pathogens, including P. gingivalis and Actinobacillus actinomycetemcomitans, exhibit some strain-dependent resistance to β-defensins (34, 48). β-Defensins are found in saliva and gingival crevicular fluid, are expressed by the oral epithelium, tongue, and salivary glands (7, 17, 18, 22, 23, 40, 57), and are upregulated in response to inflammatory stimuli (23, 28, 36). Yet T. denticola thrives in this seemingly hostile environment. Because successful treatment of periodontal disease is dependent on a decrease in the number of periodontal pathogens, including oral treponemes (2, 19, 24, 37, 46, 60, 69), understanding how T. denticola is able to avoid killing by these peptides may provide insight into the development of effective therapies. MATERIALS AND METHODS Bacterial strains and culture. T. denticola strains 35404, 33520, and 33521 were a gift from Pamela Braham (University of Washington, Seattle). Strain K1 (dentilisin mutant) and its ATCC 35405 parent were a gift from Kazuyuki Ishihara (Tokyo Dental College, Chiba, Japan) (31). Dentilisin activity was detected by T. denticola-induced cleavage of a chromogenic target of chymotrypsin-like activity, succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (SAAPNA) (Sigma Chemicals, St. Louis, MO) (54). T. denticola was maintained in GM-1 medium (6) or a derivative of OMIZ-W, P4 (75), in an anaerobic jar at 37°C. OMIZ-P4 (ATCC medium 2131) was prepared without sugars, 1,4-dihydroxy-2-naphthoic acid, cholesterol, yeast extract, neopeptone, or human serum. K1 cultures (in GM-1 medium) were supplemented with 40 μg/ml erythromycin. Escherichia coli strain ML35 was obtained from the American Type Culture Collection, Rockville, MD, and was maintained in Luria-Bertani medium at 37°C. The Staphylococcus aureus 113 dlt mutant was a gift from Amanda Jones (University of Washington) and was maintained in Todd-Hewitt broth at 37°C. Chemicals and reagents. All chemicals and reagents were purchased from Sigma Chemicals, unless indicated otherwise. Carbonyl cyanide 3-chlorophenylhydrazone (CCCP) was resuspended in dimethyl sulfoxide (DMSO) at a concentration of 0.1 mM; verapamil hydrochloride was resuspended at a concentration of 10 mg/ml in distilled H2O; acriflavine was resuspended at a concentration of 1 mg/ml in 100% ethanol; reserpine was resuspended at a concentration of 10 mg/ml in 100% ethanol; and sodium orthovanadate was resuspended at a concentration of 0.1 M in distilled H2O. All chemicals were prepared immediately before use. Defensin killing assay. Log-phase cultures of T. denticola, E. coli, or S. aureus 113 dlt were centrifuged at 10,000 × g for 10 min at 20°C. The bacteria were washed once and resuspended in 10 mM sodium phosphate buffer (pH 7.2) containing 1% Trypticase soy broth (TSB). A total of 1 × 105 motile treponemes in 1 ml were added to triplicate tubes and incubated with 10 μg/ml of human β-defensin 2 (hβD-2) or hβD-3 (Peptides International, Lexington, KY) or 80 μg/ml erythromycin (positive control for killing) at 37°C anaerobically for 0.5 to 4 h. In some experiments, efflux pump inhibitors, such as CCCP (final concentration, 35 μM), reserpine (10 μg/ml), verapamil (20 μg/ml), or sodium orthovanadate (50 μM), or equivalent amounts of their solvents were included in the killing assay mixture 10 min before addition of the defensin peptide. Recently, Dorschner et al. (21) indicated that the inhibitory effects of salt on β-defensin activity could be overcome by cultivating bacteria in mammalian ionic conditions; therefore, we also tested the sensitivity to hβD-2 and -3 of T. denticola grown in medium adapted from minimal essential medium containing 27 μM sodium bicarbonate as defined by Dorschner et al. but with additives that permit T. denticola growth. No difference in T. denticola sensitivity to hβD-2 and -3 was observed in this medium (data not shown). T. denticola viability was determined by determining the number of CFU. After incubation with human β-defensin, bacterial suspensions were diluted 1:30 in 10 mM sodium phosphate buffer containing 1% TSB (pH 7.2) and then added to 25 ml semisolid GM-1 medium (with 0.5% Noble agar and 0.5% gelatin) in 25-cm2 tissue culture flasks and allowed to solidify at room temperature. Five milliliters of TSB containing 1% Noble agar was overlaid as a sealant. The flasks were incubated anaerobically at 37°C for 7 to 10 days, and the CFU were counted. As controls for human β-defensin activity, E. coli ML35 and the S. aureus 113 dlt mutant were incubated in the same manner, and viability was determined by plate counting on Luria-Bertani medium and Todd-Hewitt medium, respectively. Student's t test assuming unequal variances was used to determine significance; a P value of ≤0.05 was considered significant. Acriflavine uptake. T. denticola mid- to late-log-phase cultures were collected by centrifugation at 10,000 × g for 10 min. The pellets were washed once with 10 mM sodium phosphate buffer containing 1% TSB and resuspended to a concentration of 1 × 108 treponemes/ml. Then 100 μl/well was added to Perkin-Elmer Opti96 black plates, and this was followed by addition of 10 μl/well of 350 μM CCCP, 100 μg/ml reserpine, 200 μg/ml verapamil, 500 μM sodium orthovanadate, or an appropriate solvent. Acriflavine is a fluorescent dye; as it binds DNA, its fluorescence is quenched (13). We added 10 μl of a 10.25-μg/ml acriflavine solution to appropriate wells, and the fluorescence was measured immediately and at 2- to 3-min intervals at 37°C using a Perkin-Elmer Fusion instrument with an excitation wavelength of 440 (bandwidth, 35) and an emission wavelength of 505 (bandwidth, 20). The percent quenching of acriflavine fluorescence compared with the control was calculated as follows: 100 − ([average relative fluorescence units of wells with efflux inhibitor/average relative fluorescence units of wells with solvent only] × 100). For example, the data indicated that there was 43% more acriflavine quenching in the presence of CCCP than in the presence of the control, which was calculated as follows: 100 − ([4,515 relative fluorescence units for T. denticola with CCCP/8,037 relative fluorescence units for T. denticola with DMSO] × 100). Binding of β-defensin to bacteria. Eppendorf tubes were treated with phosphate-buffered saline (PBS) containing 1% Tween 20 for 1 h at room temperature to block nonspecific protein binding and then washed once with PBS containing 0.05% Tween 20. Five hundred microliters of T. denticola (grown in either GM-1 medium or serum-free chemically defined medium), E. coli, or S. aureus 113 dlt at a concentration of 1 × 108 cells/ml in 10 mM sodium phosphate buffer was incubated with biotinylated β-defensin 2 or 3 (Global Peptide, Fort Collins, CO) at a concentration of 10 μg/ml for 0 to 4 h at 37°C. The maximum peptide binding was observed within 30 min (data not shown). Bacteria were collected by centrifugation at 14,000 × g for 30 min at room temperature. The supernatants were discarded, and the bacteria were washed once with PBS containing 0.05% Tween 20. To exhaust the endogenous peroxidase activity, the bacteria were resuspended in 50 μl of 3% hydrogen peroxide and incubated for 5 min at room temperature. The bacteria were washed again with PBS containing 0.05% Tween 20, resuspended in 50 μl PBS, transferred to new tubes, and stored at −20°C. T. denticola cells remained intact under these conditions, as determined by dark-field microscopy (data not shown). In experiments to detect internalized defensin, bacteria were treated with 125 μl of 0.05% Triton X-100 for 5 min at room temperature prior to the final wash. To differentiate between binding and uptake, experiments were conducted at 4 and 37°C; there were no significant temperature-dependent differences in the amount of peptide bound to any of the bacteria tested (data not shown). After addition of 50 μl strepavidin-horseradish peroxidase (HRP) (Vectastain ABC kit; Vector Laboratories, Burlingame, CA) and incubation for 1 h at 37°C, bacteria were washed four times by centrifugation at 14,000 × g for 30 min and then resuspended in 50 μl PBS and transferred to an enzyme-linked immunosorbent assay plate (Maxisorp; Nunc, Rochester, NY). Beta-defensins were detected by addition of 100 μl of 3,3,5′,5-tetramethylbenzidine substrate. The reaction was terminated by addition of 100 μl of 2 N H2SO4, and the absorbance at 450 nm was determined. The approximate surface area of T. denticola was determined using the following parameters: average length of T. denticola cell, 11 μm; average width of T. denticola cell, 0.18 μm; wavelength, 0.9 μm; and amplitude, 0.15 μm (12). The length was divided by the wavelength to obtain 12.2 waves per bacterium. The total additional length from the height of waves was calculated as follows: 12.2 waves/bacterium × amplitude, which resulted in a total length of 1.83 μm. The total length of a “stretched-out” T. denticola cell is 12.83 μm. The bacterium was considered to be a cylinder, and the surface area of a cylinder is equal to 2(πr2) + (2πr)h, where the r is the radius and h is the height. If the radius of a T. denticola cell was one-half the width and the height was the total length of T. denticola, the surface area of T. denticola was approximately 7.3 μm2. The surface area of E. coli was 4.4 μm2, determined using the formula for the surface area of a cylinder with 0.5 μm as width and 1 μm as height, and the surface area of S. aureus was 3.14 μm2 (the surface area of a sphere is 4 πr2, and the radius was 0.5 μm). The correlation between the percentage of bacteria killed in the presence of peptide and the ratio of absorbance to surface area was determined by linear regression. RESULTS T. denticola does not mask its surface with host proteins as a mechanism of defensin resistance. Cloaking of peptide-binding sites on the outer membrane of the bacterium by host proteins is a possible mechanism by which T. denticola might resist β-defensin killing. Both T. denticola and Treponema pallidum have been reported to bind host serum proteins (3, 25). To test whether host proteins present in serum contribute to T. denticola's resistance to β-defensins, T. denticola 35404 was grown in a chemically defined medium which lacks serum or other proteins and in serum-containing GM-1 medium. Bacteria were collected by centrifugation, washed as described previously, and incubated in the presence or absence of 10 μg/ml hβD-2 or -3 for 4 h. The bacteria were diluted, and the numbers of CFU were determined; E. coli ML35 and S. aureus 113 dlt were used as controls for defensin activity. Treponemes grown in the chemically defined medium were no more susceptible to killing by hβD-2 or -3 than treponemes grown in GM-1 medium with serum were (Fig. (Fig.1).1
T. denticola major outer membrane protease, dentilisin, is not responsible for the lack of sensitivity to β-defensins. We previously found that T. denticola proteases do not degrade β-defensins as an explanation for the decreased vulnerability to defensins, using two independent methods: by demonstrating that there was not increased killing by hβD-2 in the presence of multiple protease inhibitors and by demonstrating that the presence of T. denticola (with its full proteolytic capability) did not protect E. coli from killing by hβD-2 during coincubation (9). The mutant T. denticola K1 lacks the major outer membrane protease, dentilisin (31). The presence or absence of chymotrypsin-like protease activity was confirmed by cleavage of a chromogenic substrate, SAAPNA; K1 did not cleave SAAPNA, while its parent strain showed the expected activity (data not shown). To test whether the lack of chymotrypsin-like protease activity in this mutant increased the sensitivity to β-defensins, the T. denticola K1 mutant and its parent strain (35405) were incubated in the presence of 10 μg/ml hβD-2 or -3 for 4 h in 10 mM sodium phosphate buffer. The bacteria were then diluted, and the numbers of CFU were determined. S. aureus 113 dlt was used as a control for peptide activity. Experiments were conducted three times with triplicate replicates. There was no difference between the amount of the K1 mutant killed and the amount of its parent strain killed. For hβD-2, the percentages of the ATCC 35405 parent, K1 mutant, and S. aureus 113 dlt killed were 33% ± 9%, 26% ± 10%, and 65% ± 9%, respectively. For hβD-3, the percentages of the ATCC 35405 parent, K1 mutant, and S. aureus 113 dlt killed were 31% ± 9%, 27% ± 12%, and 92% ± 3%, respectively. These results confirm that dentilisin activity is not responsible for T. denticola's relative insensitivity to β-defensins. Binding of β-defensins to T. denticola. Another mechanism of T. denticola's resistance to β-defensins may be related to the overall charge of the bacterium. Defensins are cationic and likely bind negatively charged bacterial structures, such as lipopolysaccharide (LPS), as a preliminary step in bacterial killing. An analysis of the T. denticola genome (ATCC 35405) indicated that there is a lack of LPS structural genes (66). The surface of T. denticola 33520 is not highly negatively charged (14), and T. denticola 33521 outer membrane lipids are dominated by positively charged uronic acid, which may prevent the electrostatic interactions involved in defensin binding (64). Thus, the lack of a negative surface charge may result in reduced binding of defensins to T. denticola compared to the binding to other bacteria. To examine this possibility, biotinylated hβD-2 or -3 was incubated with T. denticola 35404, 33520, 33521, the ATCC 35405 parent, the ATCC 35405 K1 dentilisin mutant, E. coli ML35, or S. aureus 113 dlt. While all five T. denticola strains bound measurable amounts of hβD-2, they bound significantly less peptide than either E. coli or S. aureus 113 dlt bound when the values were adjusted for surface area (Fig. (Fig.2A).2A
T. denticola ABC efflux pumps are not involved in defensin resistance. Efflux of cationic peptides as a resistance mechanism has been observed in Neisseria and Yersinia species (5, 56, 58, 67, 72). To test whether the numerous ATP-binding cassette (ABC) efflux pumps present in the T. denticola genome (66) are involved in defensin resistance, the pump activity was assessed by using three known inhibitors of ABC pumps: verapamil, reserpine, and sodium orthovanadate (35, 59). To ensure that the pump inhibitors were active, a fluorescent dye, acriflavine, was used. As acriflavine is taken up by bacteria, it binds DNA, eliminating the dye's fluorescence (13). Acriflavine quenching occurs at a higher rate in the absence of active efflux pumps (13). As shown in Fig. Fig.4,4
Proton motive force uncoupler increases T. denticola sensitivity to hβD-3. CCCP is a protonophore whose addition to cells results in instantaneous dissipation of the electrochemical gradient of protons (proton motive force) across the cytoplasmic membrane. CCCP has been shown to increase the susceptibility of some bacteria to antimicrobial peptides (49) by inhibiting peptide efflux from the cytoplasm. To assess the activity of CCCP, the acriflavine assay described above was performed. As shown in Fig. Fig.5A,5A
DISCUSSION The discovery of naturally occurring antimicrobial peptides has resulted in much interest in the scientific, dental, and medical communities. In this age of antibiotic resistance, the idea of using natural antimicrobial peptides or their synthetic derivatives to combat bacterial and fungal infections is particularly appealing. The use of antimicrobial peptides as dental therapeutics to combat periodontal disease and caries has been posited, and a number of oral microbes have demonstrated sensitivity to these peptides in vitro (34, 41, 43, 44, 47, 48). However, we have demonstrated that T. denticola and several other oral treponemes are not vulnerable to human β-defensins (9, 10). T. denticola is part of the “red complex” of periodontal pathogens associated with severe periodontal disease (70), and good therapeutic outcomes require a decrease in the number of periodontal pathogens, including oral treponemes (2, 19, 24, 37, 46, 60, 69). A number of potential mechanisms may be used by T. denticola to resist killing by human β-defensins. One possibility is that T. denticola cloaks itself in host serum proteins derived from the culture media or saliva. Both T. denticola and the syphilis spirochete T. pallidum have been reported to bind host proteins to their outer sheaths, perhaps as a mechanism for host mimicry immune evasion or as a physical barrier to specific antibodies (3, 25). In this study we examined the sensitivity of T. denticola grown in a chemically defined medium lacking serum or other host proteins to hβD-2 and -3 and found that the absence of host proteins in the growth medium has no effect on T. denticola's sensitivity to the peptides. In addition, there was no difference in the binding of hβD-2 or -3 to T. denticola grown in the absence of serum. While binding of host serum proteins to T. denticola is probably important for treponeme-host interactions, masking of the bacterium's outer surface is not required for resistance to β-defensin killing. Some bacteria employ proteases to destroy antimicrobial peptides. For example, S. aureus aureolysin degrades the human epithelial antimicrobial peptide LL-37, and strains that produce more of this protease are less susceptible to killing by LL-37 (68). ZapA, a metalloprotease from Proteus mirabilis that indiscriminately degrades a number of host proteins, inactivates LL-37 and hβD-1 (4). We previously showed that proteolytic destruction of hβD-2 is not responsible for T. denticola's invulnerability to defensins by two independent methods (9). In this study, we tested the sensitivity of a protease mutant, K1, which lacks the major outer membrane protease, dentilisin (32). Dentilisin is a chymotrypsin-like protease which can degrade the small chemokine interleukin-8 (20). There was no difference between the vulnerability of the mutant to defensins and the vulnerability of its parent strain, demonstrating that dentilisin activity plays no role in T. denticola's sensitivity to defensins. These data corroborate our previous observations that T. denticola's impressive proteolytic activity is not involved in its avoidance of defensin killing (9). The available evidence suggests that T. denticola lacks a traditional negatively charged LPS, and the outer membrane of at least one strain, 33521, is dominated by a positively charged uronic acid species (15, 64, 66). It is possible that β-defensins do not bind well to the surface of the organism. Indeed, alteration of the surface charge by decoration of LPS or lipoteichoic acid with positively charged moieties is the most common mechanism employed by bacteria to avoid killing by cationic peptides. For example, lipid A modification plays a role in Haemophilus influenzae resistance to human β-defensins (71), and some S. aureus isolates have teichoic acids decorated with d-alanine- or l-lysine-modified phospholipids; mutants lacking these modifications are vulnerable to β-defensins (14, 51, 52). In this study, we measured the binding of β-defensins to T. denticola by strepavidin-HRP detection of biotinylated hβD-2 and -3 incubated with the bacteria. In order to compare binding of labeled defensin (as measured by absorbance) by T. denticola to binding by the smaller organism S. aureus or E. coli, we normalized the data by accounting for surface area. T. denticola binds significantly less hβD-2 than susceptible E. coli or S. aureus binds when the data are expressed as a ratio of absorbance to surface area. Similar results were obtained with labeled hβD-3. These results support the hypothesis that β-defensin peptides interact poorly with T. denticola's outer surface. Interestingly, T. denticola is resistant to polymyxin B, another cationic peptide that interacts strongly with LPS and other negatively charged bacterial surface structures (1, 27). Several studies have demonstrated that spirochetes which lack LPS are also relatively resistant to antimicrobial peptides, while Leptospira strains, which have a traditional LPS, have sensitivities comparable to those of other gram-negative organisms (8, 16, 61, 65, 74). While the structure and amphipathic nature of antimicrobial peptides are certainly involved, the overall charge has repeatedly been demonstrated to be an important consideration in peptide binding and killing of microorganisms (29, 30, 33, 63, 76). Our data suggest that there is a correlation between the amount of peptide bound to a bacterium and the level of killing. Efflux pumps in bacteria can recognize a variety of amphipathic molecules; certain efflux pumps are involved in the resistance of Neisseria gonorrhoeae and Yersinia enterocolitica, as well as other bacteria, to antimicrobial peptides and other toxic cationic compounds (5, 11, 42, 53, 72). According to the recently published genome sequence, T. denticola possesses an unusually large number of ABC efflux pumps, as well as several homologs of the NorM family of efflux pumps (66). In N. gonorrhoeae and Neisseria meningitidis, a NorM homolog is responsible for the efflux of cationic compounds, including the fluorescent dye acriflavine (56). T. denticola actively effluxes acriflavine from its cytoplasm, and in the presence of efflux inhibitors, T. denticola is unable to remove acriflavine, which accumulates inside the cell. These data indicate that at least some of T. denticola's efflux pumps are active and involved in removal of a cationic compound. However, three inhibitors of ABC pumps (verapamil, reserpine, and sodium orthovanadate) had no effect on T. denticola's susceptibility to hβD-2 or -3, suggesting that while ABC pumps may be involved in the efflux of some cationic compounds, they are not involved in β-defensin resistance. Other efflux systems encoded in the T. denticola genome (66), such as MATE transporters, may still be involved in T. denticola's relative resistance to β-defensins. Transport of material from the cytoplasm across bacterial membranes requires energy in the form of a proton gradient, and disruptors of the proton motive force are often used to examine the role of efflux in resistance to antibiotics (50, 55). A proton motive force inhibitor, CCCP, significantly increases T. denticola's susceptibility to killing by hβD-3, but it had no effect on T. denticola's sensitivity to hβD-2; similar results were observed for incubation times ranging from 0.5 to 4 h (data not shown). The increased killing of T. denticola in the presence of CCCP and hβD-3 appears to be synergistic rather than additive (e.g., when CCCP and hβD-3 killing values were added separately, the result was 24% ± 10% killing, while when CCCP and hβD-3 were incubated together, the result was 67% ± 10% killing). To address whether CCCP treatment increases the amount of peptide internalized by T. denticola, we measured the association of hβD-2 and -3 with T. denticola in the presence of CCCP. When cells were permeabilized to determine the total amount (surface plus internalized) of defensin associated with T. denticola, the amount of hβD-3, but not the amount of hβD-2, was significantly increased in the presence of CCCP. While the results are not conclusive, association of increased amounts of hβD-3 with T. denticola in the presence of a proton motive force inhibitor suggests that efflux has a role in the T. denticola insensitivity to hβD-3. We are continuing to examine the role of efflux in defensin resistance. Most likely, T. denticola employs more than one strategy to avoid killing by host antimicrobial peptides. Our data support a model in which T. denticola uses a combination of decreased peptide binding plus active efflux of any hβD-3 peptide which manages to enter the cytoplasm in order to withstand killing by hβD-3. The relative resistance to hβD-2 may simply be due to decreased binding of this peptide; hβD-3 has a higher positive charge than hβD-2 (+11 versus +6) and exhibits more efficient binding and killing of T. denticola (compare Fig. Fig.2B2B In this setting, treponemes may serve as a protective physical barrier between epithelium-derived antimicrobial peptides and other defensin-sensitive bacteria involved in periodontal disease, thus contributing to the survival of these bacteria in the gingival crevice. Acknowledgments We thank Heidi Pecoraro for manuscript preparation and Lorenzo Giacani and Barbara Molini for technical assistance. This work was supported by Public Health Service grant DE015354 from the National Institute of Dental and Craniofacial Research. C.A.B. was supported by Cross-Disciplinary Dental Science Research Training Grant DE007023 from the National Institute of Dental and Craniofacial Research. Notes Editor: V. J. DiRita Footnotes Published ahead of print on 26 February 2007.REFERENCES 1. Abramson, I. J., and R. M. Smibert. 1971. Bactericidal activity of antimicrobial agents for treponemes. Br. J. Vener. Dis. 47:413-418. [PubMed] 2. Aimetti, M., F. Romano, I. Torta, D. Cirillo, P. Caposio, and R. Romagnoli. 2004. Debridement and local application of tetracycline-loaded fibres in the management of persistent periodontitis: results after 12 months. J. Clin. Periodontol. 31:166-172. [PubMed] 3. Alderete, J. F., and J. B. Baseman. 1979. Surface-associated host proteins on virulent Treponema pallidum. Infect. Immun. 26:1048-1056. [PubMed] 4. Belas, R., J. Manos, and R. Suvanasuthi. 2004. Proteus mirabilis ZapA metalloprotease degrades a broad spectrum of substrates, including antimicrobial peptides. Infect. Immun. 72:5159-5167. [PubMed] 5. Bengoechea, J. A., and M. Skurnik. 2000. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol. Microbiol. 37:67-80. [PubMed] 6. Blakemore, R. P., and E. Canale-Parola. 1976. Arginine catabolism by Treponema denticola. J. Bacteriol. 128:616-622. [PubMed] 7. Bonass, W. A., A. S. High, P. J. Owen, and D. A. Devine. 1999. Expression of beta-defensin genes by human salivary glands. Oral Microbiol. Immunol. 14:371-374. [PubMed] 8. Borenstein, L. A., M. E. Selsted, R. I. Lehrer, and J. N. Miller. 1991. Antimicrobial activity of rabbit leukocyte defensins against Treponema pallidum subsp. pallidum. Infect. Immun. 59:1359-1367. [PubMed] 9. Brissette, C. A., and S. A. Lukehart. 2002. Treponema denticola is resistant to human beta-defensins. Infect. Immun. 70:3982-3984. [PubMed] 10. Brissette, C. A., L. G. Simonson, and S. A. Lukehart. 2004. Resistance to human beta-defensins is common among oral treponemes. Oral Microbiol. Immunol. 19:403-407. [PubMed] 11. Brown, M. H., I. T. Paulsen, and R. A. Skurray. 1999. The multidrug efflux protein NorM is a prototype of a new family of transporters. Mol. Microbiol. 31:394-395. [PubMed] 12. Chan, E. C., R. Siboo, T. Keng, N. Psarra, R. Hurley, S. L. Cheng, and I. Iugovaz. 1993. Treponema denticola (ex Brumpt 1925) sp. nov., nom. rev., and identification of new spirochete isolates from periodontal pockets. Int. J. Syst. Bacteriol. 43:196-203. [PubMed] 13. Chen, J., Y. Morita, M. N. Huda, T. Kuroda, T. Mizushima, and T. Tsuchiya. 2002. VmrA, a member of a novel class of Na+-coupled multidrug efflux pumps from Vibrio parahaemolyticus. J. Bacteriol. 184:572-576. [PubMed] 14. Collins, L. V., S. A. Kristian, C. Weidenmaier, M. Faigle, K. P. Van Kessel, J. A. Van Strijp, F. Gotz, B. Neumeister, and A. Peschel. 2002. Staphylococcus aureus strains lacking d-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis. 186:214-219. [PubMed] 15. Cowan, M. M., F. H. Mikx, and H. J. Busscher. 1994. Electrophoretic mobility and hemagglutination of Treponema denticola ATCC 33520. Colloids Surf. B Biointerfac. 2:407-410. 16. Cox, D. L., Y. Sun, H. Liu, R. I. Lehrer, and W. M. Shafer. 2003. Susceptibility of Treponema pallidum to host-derived antimicrobial peptides. Peptides 24:1741-1746. [PubMed] 17. Dale, B. A., J. R. Kimball, S. Krisanaprakornkit, F. Roberts, M. Robinovitch, R. O'Neal, E. V. Valore, T. Ganz, G. M. Anderson, and A. Weinberg. 2001. Localized antimicrobial peptide expression in human gingiva. J. Periodontal Res. 36:285-294. [PubMed] 18. Dale, B. A., and S. Krisanaprakornkit. 2001. Defensin antimicrobial peptides in the oral cavity. J. Oral Pathol. Med. 30:321-327. [PubMed] 19. Darveau, R. P., A. Tanner, and R. C. Page. 2000. The microbial challenge in periodontitis. Periodontology 14:12-32. 20. Deng, Q. D., Y. Han, X. Xia, and H. K. Kuramitsu. 2001. Effects of the oral spirochete Treponema denticola on interleukin-8 expression from epithelial cells. Oral Microbiol. Immunol. 16:185-187. [PubMed] 21. Dorschner, R. A., B. Lopez-Garcia, A. Peschel, D. Kraus, K. Morikawa, V. Nizet, and R. L. Gallo. 2006. The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides. FASEB J. 20:35-42. [PubMed] 22. Dunsche, A., Y. Acil, H. Dommisch, R. Siebert, J. M. Schroder, and S. Jepsen. 2002. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur. J. Oral Sci. 110:121-124. [PubMed] 23. Dunsche, A., Y. Acil, R. Siebert, J. Harder, J. M. Schroder, and S. Jepsen. 2001. Expression profile of human defensins and antimicrobial proteins in oral tissues. J. Oral Pathol. Med. 30:154-158. [PubMed] 24. Ehmke, B., T. Beikler, B. Riep, T. Flemmig, U. Gobel, and A. Moter. 2004. Intraoral dissemination of treponemes after periodontal therapy. Clin. Oral Investig. 8:219-225. 25. Fenno, J. C., M. Tamura, P. M. Hannam, G. W. Wong, R. A. Chan, and B. C. McBride. 2000. Identification of a Treponema denticola OppA homologue that binds host proteins present in the subgingival environment. Infect. Immun. 68:1884-1892. [PubMed] 26. Genco, C. A., W. L. Maloy, U. P. Kari, and M. Motley. 2003. Antimicrobial activity of magainin analogues against anaerobic oral pathogens. Int. J. Antimicrob. Agents 21:75-78. [PubMed] 27. Gutsmann, T., S. O. Hagge, A. David, S. Roes, A. Bohling, M. U. Hammer, and U. Seydel. 2005. Lipid-mediated resistance of Gram-negative bacteria against various pore-forming antimicrobial peptides. J. Endotoxin Res. 11:167-173. [PubMed] 28. Harder, J., U. Meyer-Hoffert, L. M. Teran, L. Schwichtenberg, J. Bartels, S. Maune, and J. M. Schroder. 2000. Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. Am. J. Respir. Cell Mol. Biol. 22:714-721. [PubMed] 29. Hoover, D. M., K. R. Rajashankar, R. Blumenthal, A. Puri, J. J. Oppenheim, O. Chertov, and J. Lubkowski. 2000. The structure of human beta-defensin-2 shows evidence of higher order oligomerization. J. Biol. Chem. 275:32911-32918. [PubMed] 30. Hoover, D. M., Z. Wu, K. Tucker, W. Lu, and J. Lubkowski. 2003. Antimicrobial characterization of human beta-defensin-3 derivatives. Antimicrob. Agents Chemother. 47:2804-2809. [PubMed] 31. Ishihara, K., H. K. Kuramitsu, T. Miura, and K. Okuda. 1998. Dentilisin activity affects the organization of the outer sheath of Treponema denticola. J. Bacteriol. 180:3837-3844. [PubMed] 32. Ishihara, K., T. Miura, H. K. Kuramitsu, and K. Okuda. 1996. Characterization of the Treponema denticola prtP gene encoding a prolyl-phenylalanine-specific protease (dentilisin). Infect. Immun. 64:5178-5186. [PubMed] 33. Jin, Y., J. Hammer, M. Pate, Y. Zhang, F. Zhu, E. Zmuda, and J. Blazyk. 2005. Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic beta-sheet and alpha-helical potentials. Antimicrob. Agents Chemother. 49:4957-4964. [PubMed] 34. Joly, S., C. Maze, P. B. McCray, Jr., and J. M. Guthmiller. 2004. Human beta-defensins-2 and -3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42:1024-1029. [PubMed] 35. Jonas, B. M., B. E. Murray, and G. M. Weinstock. 2001. Characterization of emeA, a NorA homolog and multidrug resistance efflux pump, in Enterococcus faecalis. Antimicrob. Agents Chemother. 45:3574-3579. [PubMed] 36. Krisanaprakornkit, S., J. R. Kimball, A. Weinberg, R. P. Darveau, B. W. Bainbridge, and B. A. Dale. 2000. Inducible expression of human beta-defensin-2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect. Immun. 68:2907-2915. [PubMed] 37. Loesche, W. J., J. Giordano, and P. P. Hujoel. 1990. The utility of the BANA test for monitoring anaerobic infections due to spirochetes (Treponema denticola) in periodontal disease. J. Dent. Res. 69:1696-1702. [PubMed] 38. Loesche, W. J., and N. S. Grossman. 2001. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin. Microbiol. Rev. 14:727-752. [PubMed] 39. Maisetta, G., G. Batoni, S. Esin, F. Luperini, M. Pardini, D. Bottai, W. Florio, M. R. Giuca, M. Gabriele, and M. Campa. 2003. Activity of human beta-defensin-3 alone or combined with other antimicrobial agents against oral bacteria. Antimicrob. Agents Chemother. 47:3349-3351. [PubMed] 40. Mathews, M., H. P. Jia, J. M. Guthmiller, G. Losh, S. Graham, G. K. Johnson, B. F. Tack, and P. B. McCray, Jr. 1999. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect. Immun. 67:2740-2745. [PubMed] 41. Mineshiba, F., S. Takashiba, J. Mineshiba, K. Matsuura, S. Kokeguchi, and Y. Murayama. 2003. Antibacterial activity of synthetic human beta-defensin-2 against periodontal bacteria. J. Int. Acad. Periodontol. 5:35-40. [PubMed] 42. Miyamae, S., H. Nikaido, Y. Tanaka, and F. Yoshimura. 1998. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42:2119-2121. [PubMed] 43. Miyasaki, K. T., A. L. Bodeau, M. E. Selsted, T. Ganz, and R. I. Lehrer. 1990. Killing of oral, Gram-negative, facultative bacteria by the rabbit defensin, NP-1. Oral Microbiol. Immunol. 5:315-319. [PubMed] 44. Miyasaki, K. T., R. Iofel, A. Oren, T. Huynh, and R. I. Lehrer. 1998. Killing of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia by protegrins. J. Periodontal Res. 33:91-98. [PubMed] 45. Miyasaki, K. T., and R. I. Lehrer. 1998. Beta-sheet antibiotic peptides as potential dental therapeutics. Int. J. Antimicrob. Agents 9:269-280. [PubMed] 46. Mousques, T., M. A. Listgarten, and R. W. Phillips. 1980. Effect of scaling and root planing on the composition of the human subgingival microbial flora. J. Periodontal Res. 15:144-151. [PubMed] 47. Nishimura, E., A. Eto, M. Kato, S. Hashizume, S. Imai, T. Nisizawa, and N. Hanada. 2004. Oral streptococci exhibit diverse susceptibility to human beta-defensin-2: antimicrobial effects of hBD-2 on oral streptococci. Curr. Microbiol. 48:85-87. [PubMed] 48. Ouhara, K., H. Komatsuzawa, S. Yamada, H. Shiba, T. Fujiwara, M. Ohara, K. Sayama, K. Hashimoto, H. Kurihara, and M. Sugai. 2005. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, beta-defensins and LL37, produced by human epithelial cells. J. Antimicrob. Chemother. 55:888-896. [PubMed] 49. Pages, J. M., M. Masi, and J. Barbe. 2005. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol. Med. 11:382-389. [PubMed] 50. Peric, M., B. Bozdogan, M. R. Jacobs, and P. C. Appelbaum. 2003. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother. 47:1017-1022. [PubMed] 51. Peschel, A., R. W. Jack, M. Otto, L. V. Collins, P. Staubitz, G. Nicholson, H. Kalbacher, W. F. Nieuwenhuizen, G. Jung, A. Tarkowski, K. P. M. van Kessel, and J. A. G. van Strijp. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 193:1067-1076. [PubMed] 52. Peschel, A., M. Otto, R. W. Jack, H. Kalbacher, G. Jung, and F. Gotz. 1999. Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274:8405-8410. [PubMed] 53. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in Gram-positive bacteria and the mycobacteria. Antimicrob. Agents Chemother. 44:2595-2599. [PubMed] 54. Que, X. C., and H. K. Kuramitsu. 1990. Isolation and characterization of the Treponema denticola prtA gene coding for chymotrypsinlike protease activity and detection of a closely linked gene encoding PZ-PLGPA-hydrolyzing activity. Infect. Immun. 58:4099-4105. [PubMed] 55. Ricci, V., and L. J. Piddock. 2000. Accumulation of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 44:2361-2366. [PubMed] 56. Rouquette-Loughlin, C., S. A. Dunham, M. Kuhn, J. T. Balthazar, and W. M. Shafer. 2003. The NorM efflux pump of Neisseria gonorrhoeae and Neisseria meningitidis recognizes antimicrobial cationic compounds. J. Bacteriol. 185:1101-1106. [PubMed] 57. Sahasrabudhe, K. S., J. R. Kimball, T. H. Morton, A. Weinberg, and B. A. Dale. 2000. Expression of the antimicrobial peptide, human beta-defensin-1, in duct cells of minor salivary glands and detection in saliva. J. Dent. Res. 79:1669-1674. [PubMed] 58. Sahl, H. G., U. Pag, S. Bonness, S. Wagner, N. Antcheva, and A. Tossi. 2005. Mammalian defensins: structures and mechanism of antibiotic activity. J. Leukoc. Biol. 77:466-475. [PubMed] 59. Sakamoto, K., A. Margolles, H. W. van Veen, and W. N. Konings. 2001. Hop resistance in the beer spoilage bacterium Lactobacillus brevis is mediated by the ATP-binding cassette multidrug transporter HorA. J. Bacteriol. 183:5371-5375. [PubMed] 60. Sakamoto, M., Y. Huang, M. Ohnishi, M. Umeda, I. Ishikawa, and Y. Benno. 2004. Changes in oral microbial profiles after periodontal treatment as determined by molecular analysis of 16S rRNA genes. J. Med. Microbiol. 53:563-571. [PubMed] 61. Sambri, V., A. Marangoni, L. Giacani, R. Gennaro, R. Murgia, R. Cevenini, and M. Cinco. 2002. Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema pallidum. J. Antimicrob. Chemother. 50:895-902. [PubMed] 62. Satcher, D. S. 2000. Oral health in America: a report of the Surgeon General. U.S. Department of Health and Human Services, National Institute of Dental and Craniofacial Research, National Institutes of Health, Rockville, MD. 63. Schibli, D. J., H. N. Hunter, V. Aseyev, T. D. Starner, J. M. Wiencek, P. B. McCray, Jr., B. F. Tack, and H. J. Vogel. 2002. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of hBD-3 against Staphylococcus aureus. J. Biol. Chem. 277:8279-8289. [PubMed] 64. Schultz, C. P., V. Wolf, R. Lange, E. Mertens, J. Wecke, D. Naumann, and U. Zahringer. 1998. Evidence for a new type of outer membrane lipid in oral spirochete Treponema denticola. Functioning permeation barrier without lipopolysaccharides. J. Biol. Chem. 273:15661-15666. [PubMed] 65. Scocchi, M., D. Romeo, and M. Cinco. 1993. Antimicrobial activity of two bactenecins against spirochetes. Infect. Immun. 61:3081-3083. [PubMed] 66. Seshadri, R., G. S. A. Myers, H. Tettelin, J. A. Eisen, J. F. Heidelberg, R. J. Dodson, T. M. Davidsen, R. T. DeBoy, D. E. Fouts, D. H. Haft, J. Selengut, Q. Ren, L. M. Brinkac, R. Madupu, J. Kolonay, S. A. Durkin, S. C. Daugherty, J. Shetty, A. Shvartsbeyn, E. Gebregeorgis, K. Geer, G. Tsegaye, J. Malek, B. Ayodeji, S. Shatsman, M. P. McLeod, D. Smajs, J. K. Howell, S. Pal, A. Amin, P. Vashisth, T. Z. McNeill, Q. Xiang, E. Sodergren, E. Baca, G. M. Weinstock, S. J. Norris, C. M. Fraser, and I. T. Paulsen. 2004. Comparison of the genome of the oral pathogen Treponema denticola with other spirochete genomes. Proc. Natl. Acad. Sci. USA 101:5646-5651. [PubMed] 67. Shafer, W. M., X. Qu, A. J. Waring, and R. I. Lehrer. 1998. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc. Natl. Acad. Sci. USA 95:1829-1833. [PubMed] 68. Sieprawska-Lupa, M., P. Mydel, K. Krawczyk, K. Wojcik, M. Puklo, B. Lupa, P. Suder, J. Silberring, M. Reed, J. Pohl, W. Shafer, F. McAleese, T. Foster, J. Travis, and J. Potempa. 2004. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 48:4673-4679. [PubMed] 69. Simonson, L. G., P. J. Robinson, R. J. Pranger, M. E. Cohen, and H. E. Morton. 1992. Treponema denticola and Porphyromonas gingivalis as prognostic markers following periodontal treatment. J. Periodontol. 63:270-273. [PubMed] 70. Socransky, S. S., A. D. Haffajee, M. A. Cugini, C. Smith, and R. L. Kent, Jr. 1998. Microbial complexes in subgingival plaque. J. Clin. Periodontol. 25:134-144. [PubMed] 71. Starner, T. D., W. E. Swords, M. A. Apicella, and P. B. McCray, Jr. 2002. Susceptibility of nontypeable Haemophilus influenzae to human beta-defensins is influenced by lipooligosaccharide acylation. Infect. Immun. 70:5287-5289. [PubMed] 72. Tzeng, Y. L., K. D. Ambrose, S. Zughaier, X. Zhou, Y. K. Miller, W. M. Shafer, and D. S. Stephens. 2005. Cationic antimicrobial peptide resistance in Neisseria meningitidis. J. Bacteriol. 187:5387-5396. [PubMed] 73. Weinberg, A., S. Krisanaprakornkit, and B. A. Dale. 1998. Epithelial antimicrobial peptides: review and significance for oral applications. Crit. Rev. Oral Biol. Med. 9:399-414. [PubMed] 74. Wu, Q., L. Xu, X. Wang, S. Li, and B. Wang. 1992. Investigation of microbicidal activity of neutrophil defensins against leptospires. J. West China Univ. Med. Sci. 23:126-129. [Chinese.] 75. Wyss, C. 1992. Growth of Porphyromonas gingivalis, Treponema denticola, T. pectinovorum, T. socranskii, and T. vincentii in a chemically defined medium. J. Clin. Microbiol. 30:2225-2229. [PubMed] 76. Zhang, L., A. Rozek, and R. E. W. Hancock. 2001. Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem. 276:35714-35722. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Clin Microbiol Rev. 2001 Oct; 14(4):727-52, table of contents.
[Clin Microbiol Rev. 2001]Int J Antimicrob Agents. 2003 Jan; 21(1):75-8.
[Int J Antimicrob Agents. 2003]Int J Antimicrob Agents. 1998 Feb; 9(4):269-80.
[Int J Antimicrob Agents. 1998]Crit Rev Oral Biol Med. 1998; 9(4):399-414.
[Crit Rev Oral Biol Med. 1998]J Clin Microbiol. 2004 Mar; 42(3):1024-9.
[J Clin Microbiol. 2004]J Bacteriol. 1998 Aug; 180(15):3837-44.
[J Bacteriol. 1998]Infect Immun. 1990 Dec; 58(12):4099-105.
[Infect Immun. 1990]J Bacteriol. 1976 Nov; 128(2):616-22.
[J Bacteriol. 1976]J Clin Microbiol. 1992 Sep; 30(9):2225-9.
[J Clin Microbiol. 1992]FASEB J. 2006 Jan; 20(1):35-42.
[FASEB J. 2006]J Bacteriol. 2002 Jan; 184(2):572-6.
[J Bacteriol. 2002]Int J Syst Bacteriol. 1993 Apr; 43(2):196-203.
[Int J Syst Bacteriol. 1993]Infect Immun. 1979 Dec; 26(3):1048-56.
[Infect Immun. 1979]Infect Immun. 2000 Apr; 68(4):1884-92.
[Infect Immun. 2000]Infect Immun. 2002 Jul; 70(7):3982-4.
[Infect Immun. 2002]J Bacteriol. 1998 Aug; 180(15):3837-44.
[J Bacteriol. 1998]Proc Natl Acad Sci U S A. 2004 Apr 13; 101(15):5646-51.
[Proc Natl Acad Sci U S A. 2004]J Infect Dis. 2002 Jul 15; 186(2):214-9.
[J Infect Dis. 2002]J Biol Chem. 1998 Jun 19; 273(25):15661-6.
[J Biol Chem. 1998]J Bacteriol. 1998 Aug; 180(15):3837-44.
[J Bacteriol. 1998]Mol Microbiol. 2000 Jul; 37(1):67-80.
[Mol Microbiol. 2000]J Bacteriol. 2003 Feb; 185(3):1101-6.
[J Bacteriol. 2003]J Leukoc Biol. 2005 Apr; 77(4):466-75.
[J Leukoc Biol. 2005]Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1829-33.
[Proc Natl Acad Sci U S A. 1998]J Bacteriol. 2005 Aug; 187(15):5387-96.
[J Bacteriol. 2005]Trends Mol Med. 2005 Aug; 11(8):382-9.
[Trends Mol Med. 2005]J Clin Microbiol. 2004 Mar; 42(3):1024-9.
[J Clin Microbiol. 2004]J Int Acad Periodontol. 2003 Apr; 5(2):35-40.
[J Int Acad Periodontol. 2003]Oral Microbiol Immunol. 1990 Dec; 5(6):315-9.
[Oral Microbiol Immunol. 1990]J Periodontal Res. 1998 Feb; 33(2):91-8.
[J Periodontal Res. 1998]Curr Microbiol. 2004 Feb; 48(2):85-7.
[Curr Microbiol. 2004]Infect Immun. 1979 Dec; 26(3):1048-56.
[Infect Immun. 1979]Infect Immun. 2000 Apr; 68(4):1884-92.
[Infect Immun. 2000]Antimicrob Agents Chemother. 2004 Dec; 48(12):4673-9.
[Antimicrob Agents Chemother. 2004]Infect Immun. 2004 Sep; 72(9):5159-67.
[Infect Immun. 2004]Infect Immun. 2002 Jul; 70(7):3982-4.
[Infect Immun. 2002]Infect Immun. 1996 Dec; 64(12):5178-86.
[Infect Immun. 1996]Oral Microbiol Immunol. 2001 Jun; 16(3):185-7.
[Oral Microbiol Immunol. 2001]J Biol Chem. 1998 Jun 19; 273(25):15661-6.
[J Biol Chem. 1998]Proc Natl Acad Sci U S A. 2004 Apr 13; 101(15):5646-51.
[Proc Natl Acad Sci U S A. 2004]Infect Immun. 2002 Sep; 70(9):5287-9.
[Infect Immun. 2002]J Infect Dis. 2002 Jul 15; 186(2):214-9.
[J Infect Dis. 2002]J Exp Med. 2001 May 7; 193(9):1067-76.
[J Exp Med. 2001]Mol Microbiol. 2000 Jul; 37(1):67-80.
[Mol Microbiol. 2000]Mol Microbiol. 1999 Jan; 31(1):394-5.
[Mol Microbiol. 1999]Antimicrob Agents Chemother. 1998 Aug; 42(8):2119-21.
[Antimicrob Agents Chemother. 1998]Antimicrob Agents Chemother. 2000 Oct; 44(10):2595-9.
[Antimicrob Agents Chemother. 2000]J Bacteriol. 2005 Aug; 187(15):5387-96.
[J Bacteriol. 2005]Antimicrob Agents Chemother. 2003 Mar; 47(3):1017-22.
[Antimicrob Agents Chemother. 2003]Antimicrob Agents Chemother. 2000 Sep; 44(9):2361-6.
[Antimicrob Agents Chemother. 2000]Oral Microbiol Immunol. 2004 Dec; 19(6):403-7.
[Oral Microbiol Immunol. 2004]